By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BioTie Therapies Corp. 

Tykistokatu 6

Turku    FIN-20520  Finland
Phone: 358-2-274-8900 Fax: 358-2-274-8910


Company News
BioTie Therapies Corp. Updates Outlook On Tozadenant And SYN120 7/30/2014 2:44:16 PM
BioTie Therapies Corp. Interim Report 1 January - 30 June 2014 7/30/2014 2:40:35 PM
Change In The Number Of Votes Relating To BioTie Therapies Corp.'s Shares 7/30/2014 9:06:04 AM
Clinical Study With BioTie Therapies Corp.''s BTT1023 In Primary Sclerosing Cholangitis Awarded External Grant Funding 7/24/2014 10:37:28 AM
BioTie Therapies Corp.: Selincro Enters The Market In Spain 7/22/2014 9:16:45 AM
BioTie Therapies Corp. Selects Bracket's CDR Systemâ„¢ For Phase 2 Trial Of Treatment Of Parkinson's Disease 7/16/2014 11:12:27 AM
BioTie Therapies Corp. Will Not Exercise Option To Buy Neurelis, Neurelis Regains Rights To Intranasal Diazepam Program 7/11/2014 6:18:03 AM
BioTie Therapies Corp.: Selincro Receives Positive Draft Guidance From UK's National Institute for Clinical Excellence (NICE) 7/10/2014 5:58:45 AM
BioTie Therapies Corp. Awarded $2 Million Grant From The Michael J. Fox Foundation For A Clinical Study With SYN120 In Parkinson's Disease Dementia 7/8/2014 6:12:19 AM
BioTie Therapies Corp.: Tozadenant Phase 2b Parkinson's Disease Study Published In Lancet Neurology 7/8/2014 6:11:09 AM